Texture Analysis of Breast DCE-MRI Based on Intratumoral Subregions for Predicting HER2 2+Status

被引:16
|
作者
Lu, Hecheng [1 ,2 ]
Yin, Jiandong [2 ]
机构
[1] Northeastern Univ, Sch Med & Bioinformat Engn, Shenyang, Peoples R China
[2] China Med Univ, ShengJing Hosp, Dept Radiol, Shenyang, Peoples R China
来源
FRONTIERS IN ONCOLOGY | 2020年 / 10卷
关键词
breast cancer; receiver operating characteristic; immunohistochemistry; magnetic resonance imaging; gene expression; IN-SITU HYBRIDIZATION; CONTRAST-ENHANCED MRI; NEOADJUVANT CHEMOTHERAPY; GENE AMPLIFICATION; MOLECULAR SUBTYPES; FEATURE-SELECTION; CANCER; HETEROGENEITY; EXPRESSION; FEATURES;
D O I
10.3389/fonc.2020.00543
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Breast tumor heterogeneity is related to risk factors that lead to aggressive tumor growth; however, such heterogeneity has not been thoroughly investigated. Purpose: To evaluate the performance of texture features extracted from heterogeneity subregions on subtraction MRI images for identifying human epidermal growth factor receptor 2 (HER2) 2+ status of breast cancers. Materials and Methods: Seventy-six patients with HER2 2+ breast cancer who underwent dynamic contrast-enhanced magnetic resonance imaging were enrolled, including 42 HER2 positive and 34 negative cases confirmed by fluorescence in situ hybridization. The lesion area was delineated semi-automatically on the subtraction MRI images at the second, fourth, and sixth phases (P-1, P-2, and P-3). A regionalization method was used to segment the lesion area into three subregions (rapid, medium, and slow) according to peak arrival time of the contrast agent. We extracted 488 texture features from the whole lesion area and three subregions independently. Wrapper, least absolute shrinkage and selection operator (LASSO), and stepwise methods were used to identify the optimal feature subsets. Univariate analysis was performed as well as support vector machine (SVM) with a leave-one-out-based cross-validation method. The area under the receiver operating characteristic curve (AUC) was calculated to evaluate the performance of the classifiers. Results: In univariate analysis, the variance from medium subregion at P-2 was the best-performing feature for distinguishing HER2 2+ status (AUC = 0.836); for the whole lesion region, the variance at P-2 achieved the best performance (AUC = 0.798). There was no significant difference between the two methods (P = 0.271). In the machine learning with SVM, the best performance (AUC = 0.929) was achieved with LASSO from rapid subregion at P-2; for the whole region, the highest AUC value was 0.847 obtained at P-2 with LASSO. The difference was significant between the two methods (P = 0.021). Conclusion: The texture analysis of heterogeneity subregions based on intratumoral regionalization method showed potential value for recognizing HER2 2+ status in breast cancer.
引用
收藏
页数:12
相关论文
共 50 条
  • [41] Intra-Tumor Partitioning and Texture Analysis of DCE-MRI Identifies Relevant Tumor Subregions to Predict Early Pathological Response of Breast Cancer to Neoadjuvant Chemotherapy
    Wu, J.
    Gong, G.
    Cui, Y.
    Li, R.
    MEDICAL PHYSICS, 2016, 43 (06) : 3751 - 3751
  • [42] Assessment of HER2 status in breast cancer
    Penault-Llorca, F
    Cayre, A
    BULLETIN DU CANCER, 2004, 91 : S211 - S215
  • [43] HER2 status in bilateral breast cancer
    Crowe, Joseph P.
    Patrick, Rebecca J.
    Rybicki, Lisa A.
    Budd, G. Thomas
    Escobar, Pedro F.
    Tubbs, Raymond R.
    Hicks, David G.
    INTERNATIONAL JOURNAL OF FERTILITY AND WOMENS MEDICINE, 2006, 51 (05) : 219 - 223
  • [44] Intratumoral and peritumoral radiomics for the pretreatment prediction of pathological complete response to neoadjuvant chemotherapy based on breast DCE-MRI
    Braman, Nathaniel M.
    Etesami, Maryam
    Prasanna, Prateek
    Dubchuk, Christina
    Gilmore, Hannah
    Tiwari, Pallavi
    Pletcha, Donna
    Madabhushi, Anant
    BREAST CANCER RESEARCH, 2017, 19
  • [45] Intratumoral and peritumoral radiomics for the pretreatment prediction of pathological complete response to neoadjuvant chemotherapy based on breast DCE-MRI
    Nathaniel M. Braman
    Maryam Etesami
    Prateek Prasanna
    Christina Dubchuk
    Hannah Gilmore
    Pallavi Tiwari
    Donna Plecha
    Anant Madabhushi
    Breast Cancer Research, 19
  • [46] Reassessment of HER2 status in HER2 negative or HER2 unknown breast cancer patients with recurrent metastatic disease by analyzing serum HER2 and HER2 status of circulating tumor cells.
    Fehm, T.
    Lane, N.
    Solomayer, E.
    Wallwiener, D.
    Uhr, J.
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S40 - S40
  • [47] HER2 status in a large, population-based cohort: Analysis of distinct HER2 subgroups
    Jensen, K. C.
    Turbin, D. A.
    Leung, S.
    Miller, M. A.
    Johnson, K.
    Norris, B.
    Hastie, T.
    McKinney, S.
    Nielsen, T. O.
    Huntsman, D. G.
    Gilks, C. B.
    West, R. B.
    MODERN PATHOLOGY, 2008, 21 : 39A - 39A
  • [48] HER2 Gene Protein Assay: A Robust Tool for Evaluating HER2 Status and Intratumoral Heterogeneity in Endometrial Cancers
    Shafi, Saba
    Nitta, Hiroaki
    Shah, Manan
    Challa, Bindu
    Parwani, Anil, V
    Li, Zaibo
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2023, 159 (05) : 464 - 473
  • [49] HER2 status in a large, population-based cohort: Analysis of distinct HER2 subgroups
    Jensen, K. C.
    Turbin, D. A.
    Leung, S.
    Miller, M. A.
    Johnson, K.
    Norris, B.
    Hastie, T.
    McKinney, S.
    Nielsen, T. O.
    Huntsman, D. G.
    Gilks, C. B.
    West, R. B.
    LABORATORY INVESTIGATION, 2008, 88 : 39A - 39A
  • [50] Radiomics Signatures Based on Multiparametric MRI for the Preoperative Prediction of the HER2 Status of Patients with Breast Cancer
    Zhou, Jing
    Tan, Hongna
    Li, Wei
    Liu, Zehua
    Wu, Yaping
    Bai, Yan
    Fu, Fangfang
    Jia, Xin
    Feng, Aozi
    Liu, Huan
    Wang, Meiyun
    ACADEMIC RADIOLOGY, 2021, 28 (10) : 1352 - 1360